Functional drug carriers formed by RGD-modified β-CD-HPG for the delivery of docetaxel for targeted inhibition of nasopharyngeal carcinoma cells-Reference-Cited by-同舟云学术

Functional drug carriers formed by RGD-modified β-CD-HPG for the delivery of docetaxel for targeted inhibition of nasopharyngeal carcinoma cells

Published:2022 Issue:28 Volume:12 Page:18004-18011
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Xu Lingling¹²,Zhou Chuan¹³,Wang Fan⁴,Liu Huiqin¹³,Dong Guangyuan¹³,Zhang Siyi¹²,Liu Tao¹²^ORCID

Affiliation:

1. Department of Otolaryngology-Head and Neck Surgery, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510080, China

2. The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong 510515, China

3. Shantou University Medical College, Shantou, 515063, PR China

4. Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China

Abstract

A new RGD targeting drug carrier based on HPG-modified β-CD has been synthesized. This carrier showed excellent biocompatibility and targeting ability. The obtained NPs could effectively inhibit the proliferation of tumor cells.

Funder

Natural Science Foundation of Guangdong Province

Guangdong Provincial People's Hospital

Publisher

Royal Society of Chemistry (RSC)

Subject

General Chemical Engineering,General Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/RA/D2RA02301F

Reference37 articles.

1. The prevalence and prevention of nasopharyngeal carcinoma in China

2. Docetaxel/2-Hydroxypropyl β -Cyclodextrin Inclusion Complex Increases Docetaxel Solubility and Release from a Nanochannel Drug Delivery System